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AbsTrACT
Progressive cone and cone-rod dystrophies are a clinically 
and genetically heterogeneous group of inherited 
retinal diseases characterised by cone photoreceptor 
degeneration, which may be followed by subsequent 
rod photoreceptor loss. These disorders typically present 
with progressive loss of central vision, colour vision 
disturbance and photophobia. Considerable progress 
has been made in elucidating the molecular genetics 
and genotype–phenotype correlations associated with 
these dystrophies, with mutations in at least 30 genes 
implicated in this group of disorders. We discuss the 
genetics, and clinical, psychophysical, electrophysiological 
and retinal imaging characteristics of cone and cone-rod 
dystrophies, focusing particularly on four of the most 
common disease-associated genes: GUCA1A, PRPH2, 
ABCA4 and RPGR. Additionally, we briefly review 
the current management of these disorders and the 
prospects for novel therapies.
InTroduCTIon
Inherited retinal diseases (IRDs) are a large group of 
clinically and genetically heterogeneous conditions 
which constitute the leading cause of legal blindness 
in England and Wales among working-age adults, 
and the second most common in childhood.1 One 
subgroup of IRDs is the progressive cone dystro-
phies (CODs) and cone-rod dystrophies (CORDs), 
characterised by the primary degeneration of cone 
photoreceptors often with later rod involvement. 
Their estimated incidence ranges from 1 in 20 
000–100 000.2 3
Inherited disorders of cone function are clas-
sically divided into two subtypes: stationary4 and 
progressive.5 The stationary cone disorders (cone 
dysfunction syndromes) are congenital/early-infan-
tile onset and give rise to purely cone dysfunction, 
whereas progressive cone dystrophies are of later 
onset and usually also involve rod photoreceptors. 
There may, however, be overlap as some forms 
of cone dysfunction syndrome, such as achroma-
topsia,4 6 7 are associated with limited progression 
over time in a minority of subjects.
Recent advances in molecular genetics, partic-
ularly next-generation sequencing (NGS), have 
greatly improved molecular diagnosis, as the 
underlying causative genes and mutations can be 
identified in a large proportion of patients with 
COD and CORD. Many of these genes encode 
proteins involved in photoreceptor structure, or the 
phototransduction cascade.
PhoToreCePTIon And The 
PhoToTrAnsduCTIon CAsCAde
Rod photoreceptors contain rhodopsin phot-
opigment, whereas cone photoreceptors contain 
one of three types of opsin: S-cone, M-cone or 
L-cone opsin. Disease-causing sequence variants 
in the genes encoding the latter two cone opsins 
(OPN1MW and OPN1LW, respectively) are impli-
cated in X linked (XL) Bornholm eye disease and 
S-cone monochromatism.8 The latter disorder, 
although usually stationary, may show a progressive 
phenotype.
Photoreceptor activation
The first stage of phototransduction involves the 
light-induced activation of rhodopsin, in which 
its bound chromophore, 11-cis-retinal, is isomer-
ised into all-trans-retinol (figure 1).9 The resulting 
conformational change allows rhodopsin to interact 
with transducin, a guanine nucleotide-binding 
protein, to trigger dissociation of its α-subunit. In 
turn, the transducin α-subunit activates cyclic guano-
sine monophosphate (cGMP)-phosphodiesterase 
(PDE) by removal of its inhibitory γ-subunits, thus 
reducing intracellular cGMP levels and inducing 
closure of cGMP-gated (CNG) cation channels. As 
the membrane Na+-Ca2+-K+ exchanger channels 
remain active with ongoing ion exchange, the CNG 
channel closure leads to decreased intracellular 
cation levels and cell hyperpolarisation.10
Recessive variants in PDE6C and PDE6H, which 
encode the cone photoreceptor PDE α-subunits 
and γ-subunits, respectively, are associated with 
autosomal recessive (AR)-COD.11 12 Similarly, 
disease-causing variants in CNGA3 and CNGB3, 
which encode the CNG channel α-subunit and 
ß-subunit, respectively, impair the CNG-mediated 
dark current that is normally modulated by light 
inputs. These sequence variants typically result in 
achromatopsia, although some variants may cause 
an AR-COD or CORD phenotype.6 7 13
Photoreceptor deactivation
Following their activation, the phototransduc-
tion molecules enter a refractory period during 
which intracellular mechanisms return the photo-
receptor to its dark state. The activated phot-
opigment (rhodopsin) is phosphorylated by a 
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Figure 1 Schematic diagram of the phototransduction cascade including genes related to progressive cone dystrophies (CODs) and cone-rod 
dystrophies (CORDs). The cascade is triggered in the photoreceptor disc membrane by light-induced activation of rhodopsin, which subsequently 
activates transducin and phosphodiesterase (PDE). Activated PDE leads to cGMP hydrolysis to GMP. The decreased intracellular cGMP levels induce 
cation channel closure in the outer segment membrane and result in photoreceptor hyperpolarisation. Steps leading to photoreceptor activation 
are denoted by green arrows, whereas those causing photoreceptor deactivation are marked by red arrows. Corresponding genes for the proteins 
associated with CODs/CORDs are indicated by dashed lines. COD-associated genes are coloured in light blue and CORD-associated genes in dark blue, 
while those that can cause either phenotype are in grey. cGMP, cyclic GMP; CNG, cyclic nucleotide-gated; GCAP, guanylate cyclase-activating protein; 
GDP, guanosine diphosphate; GMP, guanosine monophosphate; GTP, guanosine triphosphate; IRBP, interphotoreceptor retinoid-binding protein; LRAT, 
lecithin retinol acyltransferase; PDE, phosphodiesterase; RDH, retinol dehydrogenase; RPE65, retinal pigment epithelium 65 kDa.
G-protein-coupled receptor kinase (rhodopsin kinase), after 
which it is preferentially bound and inactivated by arrestin. 
Another mechanism by which the photoreceptor returns to its 
basal state is via retinal guanylate cyclase (RetGC1, encoded by 
GUCY2D). This enzyme replenishes intracellular cGMP levels 
following activation by Ca2+-sensitive guanylate cyclase-acti-
vating proteins (GCAPs). The interaction of intracellular cGMP 
with membrane CNG channels mediates an open configuration 
in the latter, causing cation influx and membrane depolarisation.9
Autosomal dominant (AD)-COD and CORD phenotypes may 
be associated with variants in GUCA1A, which encodes the GCAP1 
protein. The common p.(Tyr99Cys) substitution is most associated 
with COD,14 but also with a range of other phenotypes,15 while 
the p.(Pro50Leu) variant often results in CORD.16 In contrast, 
GUCY2D variants are arguably associated with less phenotypic 
variability and result in AD-CORD.17 The degree of rod involve-
ment is, however, milder in GUCY2D single-variant families 
compared to those with complex sequence variants.18 19
GeneTIC And ClInICAl ChArACTerIsTICs oF Cod And 
Cord
Molecular pathology
To date, mutations in 32 genes are reported to cause COD or 
CORD (table 1). There are currently 6 identified genes that 
predominantly cause COD and 22 that lead to CORD. However, 
there is considerable overlap with the majority of genes associ-
ated with rod involvement over time.
The proteins encoded by these genes perform a diverse range 
of functions in the photoreceptor, including phototransduction 
(as outlined above), outer segment (OS) morphogenesis (CDHR1, 
PROM1, PRPH2),20–22 intraflagellar transport (RAB28, RPGR)23 24 
and neurotransmitter release (RIMS1, UNC119).25 26
In order to assess the relative contribution of each gene in 
each mode of inheritance (AD, AR and XL), all publicly avail-
able literature on CODs and CORDs (PubMed search November 
2018) in which unrelated probands were genetically investigated 
was analysed (online supplementary tables 1–3). The number of 
patients with COD/CORD secondary to disease-causing variants 
in a given gene was counted as a percentage of the total number 
of COD/CORD in each cohort. Using this approach, we esti-
mated that the disease-causing gene is identified in 56.3% of 
patients with COD/CORD, while the remaining 43.7% of cases 
are unsolved (figure 2A). The majority of molecularly defined 
disease is recessively inherited, with variants in the ABCA4 gene 
accounting for 62.2% of AR-COD/CORD cases. In AD-in-
herited and XL-inherited cases, variants in GUCY2D (34.6%) 
and RPGR (73.0%) constitute the most prevalent monogenic 
causes of disease, respectively, among currently identified genes 
(figure 2B–D).
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Table 1 Summary of the identified disease-causing genes in progressive cone and cone-rod dystrophy
Classification and 
inheritance pattern
Gene 
abbreviation Gene name Gene locus Potential function
other associated 
phenotypes 
(oMIM)
Progressive cone dystrophy (Cod) 
  Autosomal recessive CACNA2D4 Voltage-dependent calcium channel alpha-2/delta-4 12p13.33 Neurotransmitter release –
CNGB3 Cyclic nucleotide-gated channel beta-3 8q21.3 Phototransduction ACHM
PDE6C Cone-specific phosphodiesterase alpha subunit 10q23.33 Phototransduction ACHM
PDE6H Cone-specific phosphodiesterase gamma subunit 12p12.3 Phototransduction ACHM
  X linked OPN1LW Long-wave-sensitive opsin 1 Xq28 Phototransduction BCM, BED
OPN1MW Medium-wave-sensitive opsin 1 Xq28 Phototransduction BCM, BED
Progressive cone-rod dystrophy (Cord) 
  Autosomal dominant AIPL1 Aryl-hydrocarbon-interacting protein-like 1 17p13.2 Tissue development LCA, RP
CRX Cone-rod homeobox-containing gene 19q13.33 Tissue development LCA, MD
GUCY2D Guanylate cyclase 2D 17p13.1 Photoreceptor recovery CACD, LCA
PITPNM3 Membrane-associated phosphatidylinositol transfer 
protein 3
17p13.2-p13.1 Tyrosine kinase signalling –
PROM1 Prominin 1 4p15.32 Outer segment morphogenesis MD, RP
PRPH2 Peripherin 2 6p21.1 Outer segment morphogenesis CACD, LCA, MD, RP
RAX2 Retina and anterior neural fold homeobox 2 19p13.3 Tissue development –
RIMS1 Protein regulating synaptic membrane exocytosis 1 6q13 Neurotransmitter release RP
UNC119 Human homologue of C.elegans UNC119 protein 17q11.2 Neurotransmitter release –
  Autosomal recessive ADAM9 A disintegrin and metalloproteinase domain 9 8p11.22 Outer segment–RPE junction –
C21ORF2 Chromosome 21 open reading frame 2 21q22.3 Ciliogenesis –
C8ORF37 Chromosome eight open reading frame 37 8q22.1 Unknown RP
CDHR1 Cadherin-related family member 1 10q23.1 Outer segment morphogenesis RP
CEP78 Centrosomal protein 78-kD 9q21.2 Ciliogenesis –
CERKL Ceramide kinase-like 2q31.3 Photoreceptor survival RP
KCNV2 Potassium voltage-gated channel subfamily V 2 9p24.2 Unknown –
POC1B Proteome of the centriole 1B 12q21.33 Intraflagellar transport –
RAB28 Ras-associated protein 28 4p15.33 Intraflagellar transport –
RPGRIP1 Retinitis pigmentosa GTPase regulator protein 1 14q11.2 Intracellular trafficking LCA
SEMA4A Semaphorin 4A 1q22 Tissue development RP
TTLL5 Tubulin tyrosine ligase-like family member 5 14q24.3 Steroid receptor signalling –
  X linked CACNA1F Voltage-dependent calcium channel alpha-1F Xp11.23 Neurotransmitter release AIED, CSNB
both
 
  Autosomal dominant GUCA1A Guanylate cyclase activator 1A 6p21.1 Photoreceptor recovery –
  Autosomal recessive ABCA4 ATP-binding cassette subfamily A member 4 1p22.1 Retinoid cycle MD, STGD
CNGA3 Cyclic nucleotide-gated channel alpha-3 2q11.2 Phototransduction ACHM
  X linked RPGR Retinitis pigmentosa GTPase regulator Xp11.4 Intraflagellar transport MD, RP
ACHM, achromatopsia; AIED, Aland Island eye disease; BCM, blue cone monochromacy; BED, Bornholm eye disease; CACD, central areolar choroidal dystrophy; CSNB, congenital 
stationary night blindness; LCA, Leber congenital amaurosis; MD, macular dystrophy; OMIM, online Mendelian inheritance in man; RP, retinitis pigmentosa; RPE, retinal pigment 
epithelium; STGD, Stargardt disease.
Clinical presentation
COD presents with loss of central vision, photophobia and 
colour vision disturbance. Since cone function is usually initially 
normal, nystagmus is often absent. COD is distinguishable 
from CORD by the absence of early nyctalopia, which occurs 
in the latter due to concomitant rod degeneration. However, 
the majority of patients with COD develop rod dysfunction or 
loss as the disease progresses.4 In most cases, CODs and CORDs 
affect colour discrimination in all three colour axes due to 
parallel cone degeneration of the three opsin subtypes. Kellner 
et al27 and Went et al28 present notable exceptions to this with 
preferential degeneration of L-opsin and S-opsin cones, respec-
tively, thereby causing a protan or tritan defect.
A longitudinal study by Thiadens et al29 demonstrated earlier 
symptomatic onset in CORD than COD (12 vs 16 years), as well 
as a more severe disease course based on psychophysical testing. 
Visual acuity in more than half of patients with CORD (n=83) 
deteriorated to legal blindness by the age of 23 years, compared 
with 48 years in COD (n=98), although there was a large degree 
of individual variability and overlap.
Clinical investigation
Psychophysical assessment
Reduced visual acuity is the earliest manifestation of COD/
CORD, generally occurring in the first decade of life and not 
significantly improved by spectacle wear.2 The presence of 
an isolated central scotoma on visual field testing is typical in 
patients with COD, but cannot be used alone for discriminating 
the diagnosis from CORD. A significant proportion of patients 
with CORD retain peripheral vision at the time of disease 
onset, and develop a peripheral scotoma up to 10 years later.29 
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Figure 2 Frequency of disease-causing genetic variants leading to progressive cone dystrophies (CODs) and cone-rod dystrophies (CORDs), using 
studies with clearly indicated cohort sizes (listed in online supplementary tables 1-3). (A) Prevalence of the mode of inheritance for CODs and CORDs. 
The underlying disease-causing gene is identified in 56.3% of COD/CORD cases, of which most (43.2%) are of autosomal recessive (AR) inheritance. 
This is followed by autosomal dominant (AD) inheritance (12.2%) and X linked (XL) inheritance (0.9%) patterns. The remaining 43.7% of patients are 
unsolved with regard to molecular causation. (B) AD inheritance of CODs and CORDs. Mutations in 10 genes are currently associated with AD-COD/
CORD, over 75% of which are accounted for by GUCY2D, PRPH2, CRX and GUCA1A. (C) AR inheritance of CODs and CORDs. Mutations in 18 genes 
are currently associated with AR-COD/CORD, of which ABCA4 is by far the most common (62.2%). (D) XL inheritance of CODs and CORDs. Mutations 
in 4 genes are currently associated with XL-COD/CORD, of which RPGR accounts for 73.0% of cases.
In general, CODs and CORDs lead to marked visual loss at an 
earlier age than retinitis pigmentosa (RP), a rod-cone dystrophy, 
and are thus arguably more severe conditions.2
Electroretinography
The earliest electroretinography (ERG) finding in COD/CORD 
is a delayed 30 Hz flicker ERG implicit time, which selectively 
assesses cone response.2 This is followed by deterioration of the 
30 Hz flicker ERG amplitude, and reduced a-wave and b-wave 
amplitudes of the single flash photopic ERG. Scotopic func-
tion is preserved in early disease, but is usually affected in late 
disease. In corroboration with psychophysical findings, longi-
tudinal ERG in CORD shows a faster rate of cone functional 
decline than in patients with COD.30
In one disorder, KCNV2-associated retinopathy, the ERG find-
ings are characteristic and diagnostic; there is an abnormal cone 
ERG with ‘supernormal’ rod responses.31 Despite its nomencla-
ture, this disorder is not associated with enhanced rod function 
measured psychophysically.32
Retinal imaging
Funduscopy in COD classically reveals a bull’s eye maculopathy, 
but may more often identify bilateral and relatively symmetrical 
retinal pigment epithelium (RPE) disturbance/atrophy with 
progression over time.5 Peripheral RPE atrophy and bone 
spicule pigmentation are observed in advanced stages of CORD, 
whereas the retinal periphery is typically normal in CODs due 
to rod preservation. White flecks have, however, been described 
at the level of the RPE,33 with such cases likely to develop rod 
dysfunction over time. Other reported findings include a dark 
choroid sign on fluorescein angiography34 and a tapetal-like 
sheen in XL-CORD.35
Fundus autofluorescence (FAF) and optical coherence tomog-
raphy (OCT) imaging have greatly improved the characterisa-
tion of IRDs. Using wide-field FAF, Oishi et al36 demonstrated 
an association between abnormal AF and the severity of func-
tional impairment in COD/CORD, also correlating the extent 
of reduced autofluorescence with symptom duration.37 These 
findings are substantiated by their correlation with ERG abnor-
malities.38 On OCT, an absent interdigitation zone is an early 
occurrence in COD and CORD, which is a band representing the 
interaction between apical processes of the RPE and the photo-
receptor OS. Progressive disruption and loss of the ellipsoid 
zone (EZ) is another notable finding, which corresponds to the 
ellipsoid portion of the photoreceptor inner segment.39 40 Reduc-
tion in EZ band reflectance may also be seen in some CODs and 
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Figure 3 Longitudinal analysis of phenotypically heterogeneous GUCA1A-associated retinopathy (p.(Tyr99Cys) substitution). Fundus 
autofluorescence (FAF) and optical coherence tomography (OCT) imaging in unrelated subjects (A and B) harbouring the p.(Tyr99Cys) (Y99C) variant 
in GUCA1A. The left column shows FAF at baseline, and the right column that at the same location on follow-up. Red arrowheads point to the 
transfoveal OCT line scan at the location denoted by red dashes on FAF. Subject (A): presented with cone dystrophy (A-I baseline) which progressed 
over a follow-up period of 8 years (A-I follow-up). High magnification (×5) of the same location in the foveal centre (A–II) at baseline and follow-up 
(left and right, respectively) shows a greater degree of disruption to the ellipsoid zone (EZ) in the latter (black arrows). Subject (B): presented with 
isolated macular dystrophy which progressed over a 4-year follow-up period. FAF and OCT scans are in the same scale; scale bar=200 µm.
CORDs.41 42 In advanced disease, outer retinal atrophy including 
the RPE is observed.
Exploration of phenotypic diversity in COD and CORD has 
been transformed over the last decade with the application of 
adaptive optics (AO) in retinal imaging.42 43 This technique has 
enabled imaging of the human retina at a cellular resolution by 
real-time measurement and correction of individual optical aber-
rations. Usually integrated with scanning light ophthalmoscopy 
(SLO), AO imaging has been used to characterise and quantify the 
central macular photoreceptor mosaic in multiple COD/CORD 
cohorts. In GUCY2D-associated AD-CORD,44 for example, 
residual cone inner segments were visualised at the fovea which 
were undetected by other imaging modalities. Longitudinal AO 
imaging thus offers utility in measuring the rate of cone cell loss 
in progressive disease with precision.45
sPeCIFIC exAMPles oF Cod And Cord
Autosomal dominant GUCA1A-associated Cod/Cord
Molecular genetics
GUCA1A is a four-exon gene encoding GCAP1, which is 
required for RetGC activation and cGMP regeneration.46 
Since it requires regulation in a Ca2+-dependent manner, 
GCAP1 contains three Ca2+-binding EF-hand motifs, structural 
alterations to which occur in most disease-causing GUCA1A 
sequence variants.47 These include the gain-in-function variants 
p.(Tyr99Cys),16 p.(Glu155Gly)48 and p.(Asp100Gly).49 These 
result in persistent stimulation of RetGC, excess cGMP levels 
in the dark and photoreceptor apoptosis secondary to Ca2+ 
dysregulation.50 51
The phenotypic variability in patients harbouring identical 
GUCA1A mutations is noteworthy. In an intrafamilial example, 
Michaelides et al15 demonstrated the p.(Tyr99Cys) missense 
variant resulting in three different dominantly inherited pheno-
types in a non-consanguineous British family: COD, CORD and 
isolated macular dystrophy (figure 3). Similarly, another study 
identified a p.(Arg120Leu) substitution as the cause of clinically 
heterogeneous macular dystrophy in a Chinese family, with 
whole exome sequencing (WES) excluding mutations in other 
IRD genes.52
Clinical assessment
Symptomatic onset usually occurs between the second and third 
decade with reduced central vision, photophobia and generalised 
dyschromatopsia. ERG studies characteristically show reduced 
cone single-flash and flicker amplitudes with a normal implicit 
time (an unusual finding in generalised retinal disease). Rod func-
tion typically remains normal, although dysfunction may occur 
over time in COD or be reduced at presentation in CORD. The 
relative preservation of rod responses in most GUCA1A-associ-
ated progressive retinal dystrophies is attributed to greater GCAP1 
expression in cones.53
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Figure 4 Fundus photography, fundus autofluorescence (FAF) and optical coherence tomography (OCT) imaging in unrelated patients with PRPH2-
associated and RPGR-associated cone-rod dystrophy (CORD). Subjects (A) and (B) possess the p.(Arg172Trp) (R172W) variant in PRPH2. Subject 
(C) possesses the c.2847_2848delinsCT, p.(E950*) variant in RPGR. Subject (A): fundus photographs of both eyes (I–II) show bilateral bull’s eye 
maculopathy-like retinal pigment epithelial (RPE) changes. FAF imaging of the left eye at baseline (III) and on 11-year follow-up (IV) displays a florid 
speckled appearance with areas of increased and decreased macular autofluorescence. The area of affected retina is substantially increased in (IV), 
with red dashes denoting the location of the OCT scan (V). The inner segment ellipsoid photoreceptor-derived layer (the ellipsoid zone, EZ) between 
the red arrows in (V) is absent. Subject (B): fundus photographs of both eyes (VI–VII) showing marked bilateral macular atrophy, peripheral areas of 
RPE atrophy and pigmentation. Corresponding FAF images are shown in (VIII–IX). This patient has severe CORD with an acuity of counting fingers 
bilaterally and constricted peripheral visual fields. Subject (C): fundus photographs of both eyes (X–XI) showing bilateral macular atrophy, which 
corresponds to the areas of decreased macular autofluorescence. FAF imaging of the right eye at baseline (XII) and on 7-year follow-up (XIII) shows 
an increase in the hypoautofluorescent area and surrounding hyperautofluorescent ring.88 The red dashes in (XIII) denote the location of the OCT scan 
(XIV), in which the temporal border of the photoreceptor layer is marked with a red arrow. At its nasal aspect, the integrity of the photoreceptor layer 
is disrupted.
Retinal imaging
Funduscopy findings are varied, ranging from mild RPE distur-
bance to extensive macular atrophy. FAF is useful in investigating 
macular abnormalities, although both areas of hypoautofluores-
cence and hyperautofluorescence have correlated with retinal 
atrophy; an increased signal at the fovea may be seen in early 
disease.5 15 52 AOSLO has identified cellular variability between two 
related patients harbouring a single 428delTinsACAC insertion/
deletion variant.54 Despite similar clinical findings, they signifi-
cantly differed in the degree of photoreceptor mosaic disruption, 
suggesting that other genetic (or environmental) factors influence 
the effect of the primary disease-causing variant.
Autosomal dominant PRPH2-associated Cord
Molecular genetics
PRPH2 is a five-exon gene encoding peripherin-2, a cell surface 
glycoprotein in the OS with an essential role in disc morpho-
genesis.55 Interactions of peripherin-2 with ROM1 and glutamic 
acid-rich domains of CNG channels support its function in disc 
stabilisation and maintenance of rim curvature.21 CORD-associ-
ated variants in PRPH2 can be attributed to the region encoding 
the second intradiscal loop between its four transmembrane 
components. This contains cysteine residues essential for intrapro-
tein folding and interprotein interactions.56 Identified missense 
variants in this region include p.(Asn244His),57 p.(Val200Glu)58 
and p.(Arg172Trp).59
Families harbouring the p.(Asn244His) or p.(Val200Glu) variant 
present with early central RPE atrophy that advances peripherally 
on disease progression, with little intrafamilial variability.57 58 In 
contrast, clinical phenotypes associated with p.(Arg172Trp) can 
vary substantially, ranging from non-penetrance to severe CORD 
(figure 4A,B).59 In addition to CORD, the p.(Arg172Trp) substi-
tution is associated with other phenotypes, including RP, macular 
dystrophy and central areolar choroidal dystrophy.59–62
Clinical assessment
PRPH2-associated CORD usually presents in the second to third 
decade with reduced central vision, photophobia and nyctalopia. 
Certain genotype–phenotype correlations have been observed, 
including p.(Arg172Trp)-PRPH2 retinopathy being associated with 
faster loss of visual acuity than the p.(Arg172Gln) variant.62
Retinal imaging
Patients vary considerably in their funduscopic appearance, 
ranging from a bull’s eye maculopathy (figure 4A) to macular 
atrophy (figure 4B). However, FAF in PRPH2-associated disease, 
including the p.(Arg172Trp) variant, demonstrates a character-
istic speckled macular appearance in most patients (figure 4A, 
III–IV).59 AOSLO imaging in p.(Arg172Trp)-associated CORD 
revealed increased cone spacing throughout the macula with 
corresponding loss of outer retinal structures on OCT.63 However, 
intrafamilial analysis of p.(Arg172Gln)-associated disease has 
shown marked variability, similar to that seen in GUCA1A-as-
sociated CORD; one family member had a completely normal 
photoreceptor mosaic, whereas two others had variable parafo-
veal cone loss.64
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Autosomal recessive ABCA4-associated Cod/Cord
Molecular genetics
ABCA4 is a 50-exon gene that encodes a retina-specific ATP-de-
pendent cassette transporter located in the curved rim of the OS 
disc membrane.65 This protein has an essential role in the removal 
of N-retinylidene-phosphatidylethanolamine (PE) from the 
luminal to cytoplasmic aspect of the OS disc membrane, which is 
produced from the reaction of PE with excess chromophores.9 If 
not exported and dissociated, N-retinylidene-PE can accumulate 
in the OS to form the toxic fluorophore, N-retinylidene-N-ret-
inylethanolamine (A2E), a component of lipofuscin.
ABCA4 is one of the most common genetic causes of IRD and 
is associated with vast phenotypic variability. Over 1000 disease-
causing variants in ABCA4 have been identified to date, with 
the resulting phenotype varying between COD, CORD and 
Stargardt disease (STGD).66 In general, biallelic null variants are 
more commonly associated with severe and earlier onset CORD 
and childhood-onset STGD,67 68 whereas biallelic missense 
variants are associated with milder disease such as later onset 
and foveal-sparing forms of STGD.69 70 Functional outcome is 
dependent on both the variant itself and interaction with other 
ABCA4 variants (and other genetic modifiers). For example, 
p.(Gly1961Glu) in the homozygous state typically results in 
a milder phenotype,71 but can be associated with more severe 
disease when combined with other variants.72
Clinical assessment
Symptomatic onset usually occurs in childhood with a central 
scotoma and rapidly progressing macular atrophy.68 The majority 
of patients have rod involvement at presentation (CORD), which 
is associated with a worse prognosis.73
Retinal imaging
Funduscopy may initially reveal a normal fundus or mild retinal 
abnormalities (such as loss of foveal reflex), as peripheral degen-
erative changes occur in later disease.74 Diagnosis can therefore 
be delayed unless FAF or OCT imaging is undertaken.68 FAF 
findings include a bull’s eye maculopathy-like appearance with 
yellow-white retinal flecks and increasing macular atrophy over 
time.73 75 OCT reveals loss of outer retinal architecture at the 
central macula.76 Longitudinal increase in abnormal AF regions 
correlates with both visual functional decline and abnormal cone 
spacing on AOSLO.77 However, cone mosaic abnormalities are 
known to precede abnormal psychophysical testing and FAF 
(figure 5).78
x linked RPGR-associated Cod/Cord
Molecular genetics
RPGR is a 19-exon gene that gives rise to two alternatively spliced 
retinal isoforms, encoded by exons 1–19 and 1–15 (+ part of 
intron 15), respectively.79 The latter isoform, also known as exon 
open reading frame 15 (ORF15), is the most highly expressed 
retinal variant and a mutational hot spot that accounts for most 
XL COD and CORD cases.5 80 The function of the C-terminal 
ORF15 sequence requires further elucidation, but is implicated 
in intraflagellar protein transport in view of its localisation at the 
photoreceptor connecting cilium.24
Most disease-causing variants in RPGR result in RP,81 but 
those leading to COD/CORD are preferentially sequestered at 
the 3’ end of the ORF15 region.82 In keeping with the majority 
of IRD, identical intrafamilial sequence variants in RPGR may 
lead to distinctly different phenotypes.83 This is exemplified 
by a Chinese family harbouring a 2403_04delAG deletion that 
resulted in both XL-RP and XL-CORD in affected men, reaf-
firming the importance of disease-modifying factors.84
Clinical assessment
RPGR-associated CORD is characterised by central visual loss, 
mild photophobia and myopia, and presents in the second to 
fourth decade in affected men.85 A longitudinal study reported 
significantly higher levels of legal blindness among RPGR-as-
sociated COD/CORD compared with RPGR-associated RP by 
the age of 40 years; high myopia was predictive of faster visual 
decline in this study.86
Retinal imaging
FAF imaging often reveals parafoveal rings of increased signal in 
RPGR-associated COD/CORD. Unlike RP, these increase in size 
with disease progression (figure 4C, XII–XIII) and are inversely 
related to ERG amplitude.87 88 They are, therefore, a potential 
endpoint in clinical trials.
MAnAGeMenT oF Cod And Cord
At present, there are no proven treatments for COD/CORD 
that halt progression or restore lost vision. Current management 
consists of symptomatic alleviation, including refractive correc-
tion, use of tinted spectacles/contact lenses for photophobia and 
low vision aids. An accurate diagnosis using molecular genetics 
is an important step to facilitate genetic counselling, advice on 
prognosis and participation in anticipated clinical trials.89
Patients with specific forms of COD/CORD can be advised 
to adopt strategies to try to slow degeneration, based on a 
knowledge of gene function or investigation of animal models. 
In GUCA1A-associated retinopathy, sleeping with the lights on 
is advocated by some clinicians for preventing accumulation of 
cGMP, which otherwise occurs at night and causes photoreceptor 
damage. In contrast, light avoidance using tinted spectacles may 
confer benefit in ABCA4-associated retinopathy by inhibiting 
A2E production,90 which produces DNA-damaging epoxides.91 
Vitamin A should also be avoided in ABCA4-associated retinop-
athy as it may enhance A2E production and, therefore, disease 
progression.92
Recent evidence has demonstrated the potential of gene 
therapy for long-term improvement in COD/CORD visual 
outcomes. Animal models of disease (murine and canine) in 
GUCA1A,93 PRPH2,94 ABCA495 and RPGR96 have shown signif-
icant increase in photoreceptor survival following gene-based 
therapies. Gene therapy encompasses multiple techniques, 
including gene replacement, gene editing and gene silencing, 
with treatment choice dependent on whether the associated 
sequence variant(s) leads to a loss or gain in function.97 Human 
treatment trials of gene replacement therapy are already under 
way for retinal disease associated with mutations in ABCA4 ( 
ClinicalTrials. gov identifier: NCT01367444) and RPGR 
(NCT03252847, NCT03116113 and NCT03316560), with 
results keenly awaited.
lIMITATIons oF GeneTIC TesTInG
While therapeutic options are on the horizon for COD/CORD 
secondary to identified disease-causing genes, the outlook 
for patients without a molecular diagnosis is more limited. 
NGS-based approaches, typically using WES, have revolution-
ised genomic analysis, but not all pathogenic mutations can be 
detected.98 Complex changes, such as inversions, translocations 
and trinucleotide repeat expansions, are mostly undetected with 
WES, and variants in deep intronic or regulatory regions are not 
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Figure 5 Fundus autofluorescence (FAF) and adaptive optics (AO) imaging in ABCA4-associated cone-rod dystrophy (CORD). (A) FAF image 
at baseline showing a central region of hypoautofluorescence surrounded by increased signal, and (B) aligned FAF image on 2-year follow-up 
demonstrating disease progression with an increased area of hypoautofluorescence. The red square signifies the superimposed adaptive optics 
scanning light ophthalmoscopy (AOSLO) montage acquired from that region on follow-up. (C) Confocal AOSLO image (photoreceptor outer segments) 
and (D) split-detection AOSLO image (photoreceptor inner segments) over the transition zone between less affected and more affected retina. For 
comparison, the side bars on the left show AOSLO images of an unaffected control at similar retinal eccentricity. Cone photoreceptors (green arrows) 
can be more reliably identified using split-detection imaging due to the poor wave guiding ability of outer segments in the confocal modality. The 
border of the transition zone (red arrows) in (C) corresponds to the presence of remnant cone inner segments in (D). The photoreceptor mosaic in 
CORD is disorganised, with altered regularity and reflectance compared to that of an unaffected eye. The number of cones is decreased in areas that 
appear healthy on FAF, demonstrating a disconnect between imaging modalities and supporting the utility of multimodal imaging. AOSLO images 
were acquired using a custom-built AOSLO housed at University College London (UCL) / Moorfields Eye Hospital (MEH); scale bar=200 µm.
sequenced. Whole genome sequencing (WGS) offers a compre-
hensive alternative. However, there still remain a proportion of 
patients who are unsolved despite WGS, due to more complex 
genetic causes that remain challenging to identify and prove 
definitively. These include rearrangements and variants in 
distant promoter/enhancer regions. Over time, improvements in 
technology and understanding will gradually reduce the number 
of patients without a genetic diagnosis.99
ConCludInG reMArks And FuTure ProsPeCTs
Advances in molecular genetic techniques, particularly NGS, 
have greatly simplified molecular diagnosis. It is hoped that the 
majority of patients will be able to have a precise molecular diag-
nosis in the future as the remaining causative genes and sequence 
variants in CODs and CORDs are identified. Similarly, advances 
in visual function testing and retinal imaging have improved 
knowledge of the relationship between genotype and pheno-
type, which is key to identifying treatment effects in clinical 
trials of novel therapies. The remaining challenge is to develop 
novel therapies that will slow degeneration or improve function, 
and it is encouraging that gene-based approaches to therapy are 
increasingly in clinical trial with the first Food and Drug Admin-
istration-approved gene therapy for LCA-RPE65 now available.
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